OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain studyProactive Investors • 12/11/25
OKYO Pharma maps out registration path with 100-patient trial of Urcosimod for neuropathic corneal painProactive Investors • 09/22/25
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal PainGlobeNewsWire • 09/22/25
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIProactive Investors • 07/19/25
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapyProactive Investors • 07/17/25
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal painProactive Investors • 07/16/25
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal PainGlobeNewsWire • 07/16/25
OKYO Pharma poised for breakout as Phase 2 trial nears results: analystsProactive Investors • 06/11/25
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summitProactive Investors • 05/19/25
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painProactive Investors • 05/01/25
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painProactive Investors • 04/30/25
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainGlobeNewsWire • 04/30/25
OKYO Pharma reports long-term shelf stability of corneal pain treatmentProactive Investors • 03/31/25
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatmentProactive Investors • 03/10/25
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believeProactive Investors • 01/31/25